Fig. 1: WNT11 is associated with CD8 + T-cell exclusion and a poor prognosis in patients with liver metastases.

a The correlation between the GSVA score of the KEGG WNT Signaling Pathway gene set and the expression of CD3D and CD8A in the LM cohort (n = 86). b The association between genes in the WNT signaling pathway and the clinical prognosis in the LM cohort. c, d Overall survival according to AFF3 and WNT11 expression in the LM cohort. e Pearson correlation analysis of AFF3 levels with WNT11 levels in the LM cohort. f Liver metastases in the LM cohort were divided into four groups based on the expression of AFF3 and WNT11. The plot shows the proportion of cancer types in the different groups. g, h The expression of CD3D and CD8A in the above four groups. i, j AFF3 and WNT11 IHC staining of primary tumors and matched liver metastases in the FUSCC_CRC_cohort (n = 71) and the SGH_PDAC_cohort (n = 50). k–n Tissue microarray analysis of AFF3 and WNT11 expression in primary tumors and matched liver metastases from the FUSCC_CRC_cohort (k, l n = 71) and SGH_PDAC_cohort (m, n n = 50). o–r Overall survival based on AFF3 and WNT11 expression in the FUSCC_CRC_cohort (o, p) and SGH_PDAC_cohort (q, r). s, t Pearson correlation of AFF3 with WNT11 expression in the FUSCC_CRC_cohort (s) and SGH_PDAC_cohort (t). a, e, s, t P-values and r-values were determined using Pearson correlation (two-tailed) without adjustment. b P-values were determined using univariate proportional hazard analysis without adjustment. c, d, o–r P-values were determined using a log-rank test. g, h P-values were determined using a one-way ANOVA followed by a post hoc Tukey’s multiple comparison test. k–n P-values were determined using a Wilcoxon rank-sum test (two-tailed). g, h, k–n In the box plots, the bounds of the box span from 25% to 75% percentile, the line represents the median, and the whiskers show the minima and maxima of data points. Source data are provided as a Source Data file.